Plymouth Meeting, PA – According to filings with the U.S. Securities and Exchange Commission, Harmony Biosciences is raising $50 Million in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, John Jacobs played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Harmony Biosciences

Harmony Biosciences, LLC, is a private biopharmaceutical company headquartered in Plymouth Meeting, PA. The company was established in October 2017 with a vision to develop and commercialize novel treatment options for people living with rare diseases. With a focus on the central nervous system, including disorders of sleep and wakefulness, Harmony Biosciences is currently working to advance the understanding of narcolepsy and provide information and resources to people who live with, and healthcare professionals who treat, this chronic, debilitating neurologic disorder.

To learn more about Harmony Biosciences, visit http://www.harmonybiosciences.com/

Contact:
John Jacobs, Chief Executive Officer
(484) 539-9800
jjacobs@harmonybiosciences.com
https://www.linkedin.com/in/john-c-jacobs/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved